NTRA vs. GH, EXAS, DGX, LH, ACHC, DOCS, NVST, LEGN, ASND, and STVN
Should you be buying Natera stock or one of its competitors? The main competitors of Natera include Guardant Health (GH), Exact Sciences (EXAS), Quest Diagnostics (DGX), Laboratory Co. of America (LH), Acadia Healthcare (ACHC), Doximity (DOCS), Envista (NVST), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Stevanato Group (STVN). These companies are all part of the "medical" sector.
Natera vs.
Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
Natera has a net margin of -66.79% compared to Guardant Health's net margin of -145.61%. Natera's return on equity of -106.67% beat Guardant Health's return on equity.
In the previous week, Natera had 9 more articles in the media than Guardant Health. MarketBeat recorded 12 mentions for Natera and 3 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.22 beat Natera's score of 0.00 indicating that Guardant Health is being referred to more favorably in the media.
Natera has higher revenue and earnings than Guardant Health. Natera is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.
90.4% of Guardant Health shares are owned by institutional investors. Comparatively, 93.8% of Natera shares are owned by institutional investors. 5.9% of Guardant Health shares are owned by company insiders. Comparatively, 10.3% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Guardant Health currently has a consensus target price of $57.64, indicating a potential upside of 138.39%. Natera has a consensus target price of $79.27, indicating a potential upside of 39.93%. Given Guardant Health's higher probable upside, analysts clearly believe Guardant Health is more favorable than Natera.
Guardant Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Natera has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Natera received 181 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 68.81% of users gave Natera an outperform vote while only 68.61% of users gave Guardant Health an outperform vote.
Summary
Natera beats Guardant Health on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
